Edwards lifts FY26 growth outlook following steady Q2 performance
Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.
Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.
The National Healthtech Access Programme aims to improve accessibility to healthtech products across the NHS.
The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare,...
Intuitive Surgical expands platforms despite market headwind
The increased importance of safety for wearable devices
What does the EU Data Act mean for businesses?
GE HealthCare launches new ultrasound system for cardiovascular imaging